Renal Cell Carcinoma | Access and Reimbursement | Implications of Physician Dispensing of Oral Oncolytics for Renal Cell Carcinoma | US | 2017
The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state laws. Direct dispensing enables physicians to more comprehensively manage their patients’ medical and therapeutic needs, which can facilitate quicker access to drugs and improve compliance. However, according to 2016 Clarivate research,MCOs are concerned about this trend because it diverts prescriptions from their or their pharmacy benefit manager’s contracted specialty pharmacies and provides an additional revenue stream for the oncology practice. New 2017 data and analysis shed further light on the trend. Understanding physician dispensing and its effect on payer reimbursement and oncologists’ prescribing habits is vital to creating a sound market access strategy for drugs to treat renal cell carcinoma and other cancers with oral options.
QUESTIONS ANSWERED
- How common is it for oncologists to dispense oral RCC drugs from within their practices or by using in-house dispensing pharmacies?
- For what reasons would physicians want to bypass MCO-directed pharmacies and use a provider-owned pharmacy or dispense from their offices?
- How do MCOs view and react to in-office dispensing by physicians, and how does this dynamic affect physician reimbursement?
- Are oncologists more likely to choose oral RCC therapies if they can stock and dispense them instead of going through a payer’s specialty pharmacy?
PRODUCT DESCRIPTION
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
